| B4 | The impact of COVID-19 on UNAIDS 90'90'90 targets calls for new HIV care models | E-poster | HIV testing and retesting |
| B40 | Self-reported antiretroviral adherence: association with maternal viral load suppression in HIV-1-infected postpartum women in Promoting Maternal and Infant Survival Everywhere (PROMISE): randomized, open label trial in sub-Saharan Africa and India | E-poster | Adherence measurement |
| B40 | Estimating minimum adherence required for plasma HIV-1 RNA viral load suppression among people who use unregulated drugs in Vancouver, Canada | E-poster | Adherence measurement |
| B40 | Utilization of antiretroviral refill histories as a predictor of future HIV viremia | E-poster | Adherence measurement |
| B42 | Region-specific laboratory reference intervals are important: a review of the data from Africa | E-poster | Ethical issues in clinical trials and treatment strategies |
| B43 | Islatravir safety analysis through week 96 from a phase 2 trial in treatment naïve adults with HIV-1 infection | On-demand oral abstract session | New strategies (2DR, rapid start) |
| B43 | Five years durability of dolutegravir + lamivudine in patients with suppressed HIV-RNA | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate versus delayed antiretroviral treatment in hospitalized persons with AIDS-defining opportunistic disease: a randomized clinical trial | E-poster | New strategies (2DR, rapid start) |
| B43 | Largely increasing amounts of patients under dual ART due to new therapeutic regimens: dual therapy regimens 2016-2020 in the German North Rhine Cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Feasibility, efficacy, and safety of Dolutegravir/Lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study | E-poster | New strategies (2DR, rapid start) |